<div id="readability-page-1">By Bhanvi Satija and Maggie Fick LONDON, Feb 13 (Reuters) - Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the United States under President Donald Trump. Investors, analysts and other people close to Garijo, who has headed Germany's Merck KGaA since 2021, told Reuters she was bold, detail-focused and got things done, but also that she had a mixed record on R&amp;D and the share ​price had dropped during her tenure. Sanofi's stock, down 25% in the last year, fell 3.5% on ‌Thursday after it said CEO Paul Hudson, 58, whose turnaround drive was stymied by a lack of new blockbuster drugs, would step down this month to be replaced by Garijo in April. &#34;The CEO change at Sanofi is a sign ⁠that R&amp;D transformation has failed or is happening too slowly,&#34; said Markus Manns, portfolio manager at Sanofi investor Union Investment. &#34;Belen's priority at Sanofi will be to increase ⁠R&amp;D productivity.&#34; Manns lauded Spaniard Garijo's handling of a complex company - Merck has units from health to technology - and a pricing ‌deal sealed with U.S. President Donald Trump ‌last year, but said she needed to step up after several R&amp;D failures at Merck. &#34;She needs to improve her R&amp;D track record.&#34; REPLACING ASTHMA BLOCKBUSTER DUPIXENT IS A MAJOR CHALLENGE Developing new drugs has proved to be Sanofi's biggest ​issue. Dupixent accounts for over 30% of the company's revenues and it has yet to ‌find a drug to take over once patents begin expiring early in the 2030s, which has weighed on Sanofi's share price. &#34;Replacing Dupixent is the key strategic challenge for Sanofi,&#34; said Nicolas Dumas, a partner at consultancy firm Roland Berger and a Sanofi employee until 2018. Vaccines, which make up ​close to a fifth of revenues, are another major issue as sales have ​dipped in recent years. ‌Hudson had flagged weakness in the segment linked to a more hostile attitude towards vaccines from the U.S. health administration. Sanofi said Garijo, who worked at the French company for years until 2011, would bring &#34;increased rigour to the implementation of&#34; the company's strategy. Garijo did not immediately respond to requests for ⁠comment. SHE WILL BECOME SANOFI'S FIRST FEMALE CEO Garijo will be Sanofi's first female CEO - and the only woman CEO at a large-cap global drugmaker after GSK's Emma ⁠Walmsley stepped down this year. She was the first woman to head a German DAX-listed company when she took on the top role at Merck KGaA. As head of Merck's pharma business, Garijo steered the group's supply chain through the COVID-19 pandemic. She oversaw deals including the group's $3.9 billion purchase of SpringWorks Therapeutics last year. However, Merck KGaA suffered setbacks in drug development during her tenure and only three new drugs made it to the market. One investor who worked with Garijo, asking not to be named, said the &#34;visible stuff&#34; - R&amp;D and ⁠business development - had ‌not gone well, while adding she had improved the structure of Merck internally and protected the company's margins. Roel Bulthuis, managing ‌partner at Syncona Limited, a London-based life sciences investment firm, said that Garijo had turned a company &#34;stuck in rules and hierarchy&#34; into a much more bold and effective entity. &#34;She... challenged ⁠executives to have guts to stand up for their decisions and actually get shit done,&#34; said Bulthuis, who previously ran M-Ventures, the corporate venture fund of Merck KGaA, during part of Garijo's tenure. A second investor who worked with Garijo said she was full of energy, dynamic and &#34;on top of things&#34; and also had deep knowledge of Sanofi. &#34;She knows the house, don't underestimate the importance of that,&#34; said the person, who also asked not to be named. CLINICAL BACKGROUND, BUT HOW LONG WILL SHE STAY? A clinical pharmacology specialist, Garijo began her career as a physician at La Paz Hospital in Madrid and is known for her operational execution and attention to detail. Garijo has &#34;more operations experience than a science background, so will be interesting to see how she can reinvigorate the ​R&amp;D department in Sanofi,&#34; said Claus Henrik Johansen, CEO of Global Health Invest, a Danish healthcare investment fund that holds Sanofi shares. Some analysts and investors said Garijo had not been on many people's radar, which caught the market slightly by surprise - and they speculated how long she would stay in her new job. &#34;I think she's a transition CEO. What ​she's good at, she's someone who can put the organisation under pressure,&#34; ‌consultant Dumas said. &#34;She's not there to stay forever.&#34; (Reporting by Bhanvi Satija and Maggie Fick in London, Patricia Weiss and Ludwig ​Burger in Frankfurt; Editing by Adam Jourdan and Barbara Lewis)</div>

IBBQ

標普全球醫療股指數 ETF - iShares

生物科技 ETF - VanEck Vectors

賽諾菲的新任首席執行官貝倫·加里霍面臨着重振公司藥物管線和應對美國特朗普總統任內疫苗懷疑主義的重大挑戰。由於賽諾菲的股價在過去一年下跌了 25%，加里霍必須提高研發生產力，並替代目前佔銷售額超過 30% 的 Dupixent 的收入。作為全球主要製藥公司首位女性首席執行官，她的運營專長將至關重要，但她的研發記錄參差不齊，引發了對她有效領導能力的質疑。分析師推測她可能是一個過渡性人物，而非長期解決方案

Analysis-Sanofi's new CEO needs to fix drug pipeline and navigate Trump

fidelity

Invesco Nasdaq Biotechnology ETF

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

美國制藥 ETF - iShares

醫藥突破 ETF - ALPS

賽諾菲集團

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

賽諾菲

分析 - 賽諾菲的新任首席執行官需要修復藥物研發管線並應對特朗普的挑戰